Skip to main content

Evaluation of 99  mTcN-MPO as a New Myocardial Perfusion Imaging Agent in Normal Dogs and in an Acute Myocardial Infarction Canine Model: Comparison with 99  mTc-Sestamibi

Molecular Imaging and Biology volume 13, pages 121–127 (2011)Cite this article

Abstract

Purpose

99  mTcN-MPO ([99  mTcN(mpo)(PNP5)]+: mpo = 2-mercaptopyridine oxide and PNP5 = N-ethoxyethyl-N,N-bis[2-(bis(3-methoxypropyl)phosphino)ethyl]amine) is a cationic 99  mTc-nitrido complex, which has favorable biodistribution and myocardial uptake with rapid liver clearance in Sprague Dawley rats. The objective of this study was to compare the biodistribution and pharmacokinetics of 99  mTcN-MPO and 99  mTc-Sestamibi in normal dogs, and to evaluate the potential of 99  mTcN-MPO as a myocardial perfusion agent in canines with acute myocardial infarction.

Methods

Five normal mongrel dogs were injected intravenously with 99  mTcN-MPO. Venous blood samples were collected via a femoral vein catheter at 0.5, 1, 2, 3, 4, 5, 10, 20, 30, 40, 60, and 90 min post-injection (p.i.). Anterior-posterior planar images were acquired by γ-camera at 10, 20, 30, 60, 90, and 120 min p.i. Regions of interest (ROIs) were drawn around the heart, liver, and lungs. The heart/liver and heart/lung ratios were calculated by dividing the mean counts in heart ROI by the mean counts in the liver and lung ROI, respectively. For comparison, 99  mTc-sestamibi was also evaluated in the same five dogs. The interval period between the two examinations was 1 week to eliminate possible interference between these two radiotracers. In addition, single positron emission computed tomography (SPECT) images in the canine infarct model were collected 24 h after myocardial infarction at 30 and 60 min after the administration of 99  mTcN-MPO (n = 4) or 99  mTc-Sestamibi (n = 4).

Results

It was found that 99  mTcN-MPO and 99  mTc-Sestamibi displayed very similar blood clearance characteristics during the first 90 min p.i. Both 99  mTcN-MPO and 99  mTc-Sestamibi had a rapid blood clearance with less than 50% of initial radioactivity remaining at 1 min and less than 5% at 30 min p.i. 99  mTcN-MPO and 99  mTc-Sestamibi both showed good heart/lung contrast. The heart/liver ratio of 99  mTcN-MPO increased with time (0.53 ± 0.06 at 10 min, 0.90 ± 0.062 at 30 min, and 1.22 ± 0.06 at 60 min p.i.), whereas the heart/liver ratio of 99  mTc-Sestamibi remained low at all time points (0.50 ± 0.03 at 10 min, 0.64 ± 0.03 at 30 min, and 0.60 ± 0.02 at 60 min p.i.). SPECT imaging studies in canines with acute myocardial infarction indicated that good visualization of the left ventricular wall and perfusion defects could be achieved at 30 min after administration of 99  mTcN-MPO but not after 99  mTc-Sestamibi.

Conclusion

The combination of reasonable heart uptake with rapid hepatobiliary excretion makes 99  mTcN-MPO a promising new radiotracer for myocardial perfusion imaging.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. Beller GA, Zaret BL (2000) Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation 101:1465–1478

    CAS  PubMed  Google Scholar 

  2. Jain D (1999) Technetium-99 m labeled myocardial perfusion imaging agents. Semin Nucl Med 29:221–236

    CAS  Article  PubMed  Google Scholar 

  3. Llaurado JG (2001) The quest for the perfect myocardial perfusion indicator...still a long way to go. J Nucl Med 42:282–284

    CAS  PubMed  Google Scholar 

  4. Kailasnath P, Sinusas AJ (2001) Comparison of Tl-201 with Tc-99 m-labeled myocardial perfusion agents: technical, physiologic, and clinical issues. J Nucl Cardiol 8:482–498

    CAS  Article  PubMed  Google Scholar 

  5. Banerjee S, Pillai MR, Ramamoorthy N (2001) Evolution of Tc-99 m in diagnostic radiopharmaceuticals. Semin Nucl Med 31:260–277

    CAS  Article  PubMed  Google Scholar 

  6. Liu S (2007) Ether and crown ether-containing cationic 99  mTc complexes useful as radiopharmaceuticals for heart imaging. Dalton Trans 12:1183–1193

    Article  PubMed  Google Scholar 

  7. Lisic EC, Heeg MJ, Deutsch E (1999) 99  mTc(L-L) +3 complexes containing ether analogs of DMPE. Nucl Med Biol 26:563–571

    CAS  Article  PubMed  Google Scholar 

  8. Tisato F, Maina T, Shao LR et al. (1996) Cationic [99  mTcIII(DIARS)2(SR)2]+ complexes as potential myocardial perfusion imaging agents (DIARS = o-phenylenebis(dimethylarsine); SR = thiolate). J Med Chem 39:1253–1261

    CAS  Article  PubMed  Google Scholar 

  9. Boschi A, Bolzati C, Uccelli L et al. (2002) A class of asymmetrical nitrido 99  mTc heterocomplexes as heart imaging agents with improved biological properties. Nucl Med Commun 23:689–693

    CAS  Article  PubMed  Google Scholar 

  10. Hatada K, Riou LM, Ruiz M et al. (2004) 99  mTc-N-DBODC5, a new myocardial perfusion imaging agent with rapid liver clearance: comparison with 99  mTc-sestamibi and 99  mTc-tetrofosmin in rats. J Nucl Med 45:2095–2101

    CAS  PubMed  Google Scholar 

  11. Hatada K, Ruiz M, Riou LM et al. (2006) Organ biodistribution and myocardial uptake, washout, and redistribution kinetics of Tc-99 m N-DBODC5 when injected during vasodilator stress in canine models of coronary stenoses. J Nucl Cardiol 13:779–790

    Article  PubMed  Google Scholar 

  12. Kim YS, He Z, Hsieh WY et al. (2006) A novel ternary ligand system useful for preparation of cationic 99  mTc-diazenido complexes and 99  mTc-labeling of small biomolecules. Bioconjug Chem 17:473–484

    CAS  Article  PubMed  Google Scholar 

  13. Liu S, He Z, Hsieh WY et al. (2006) Evaluation of novel cationic 99  mTc-nitrido complexes as radiopharmaceuticals for heart imaging: improving liver clearance with crown ether groups. Nucl Med Biol 33:419–432

    CAS  Article  PubMed  Google Scholar 

  14. He Z, Hsieh WY, Kim YS et al. (2006) Evaluation of novel cationic 99  mTc(I)-tricarbonyl complexes as potential radiotracers for myocardial perfusion imaging. Nucl Med Biol 33:1045–1053

    CAS  Article  PubMed  Google Scholar 

  15. Kim YS, He Z, Hsieh WY et al. (2007) Impact of bidentate chelators on lipophilicity, stability, and biodistribution characteristics of cationic 99  mTc-nitrido complexes. Bioconjug Chem 18:929–936

    CAS  Article  PubMed  Google Scholar 

  16. Cittanti C, Uccelli L, Pasquali M et al. (2008) Whole-body biodistribution and radiation dosimetry of the new cardiac tracer 99  mTc-N-DBODC. J Nucl Med 49:1299–1304

    CAS  Article  PubMed  Google Scholar 

  17. Kim YS, Wang J, Broisat A et al. (2008) Tc-99 m-N-MPO: novel cationic Tc-99 m radiotracer for myocardial perfusion imaging. J Nucl Cardiol 15:535–546

    Article  PubMed  Google Scholar 

  18. Kim YS, Shi J, Zhai S et al. (2009) Mechanism for myocardial localization and rapid liver clearance of Tc-99 m-N-MPO: a new perfusion radiotracer for heart imaging. J Nucl Cardiol4:571–579

    Article  PubMed  Google Scholar 

  19. Fang W, Liu Y, Zhu L et al. (2008) Evaluation of 99  mTcN-15C5 as a new myocardial perfusion imaging agent in normal dogs and canines with coronary stenosis. Nucl Med Commun 29:775–781

    CAS  Article  PubMed  Google Scholar 

  20. Krejcy K, Krumpl G, Todt H et al. (1992) Lidocaine has a narrow antiarrhythmic dose range against ventricular arrhythmias induced by programmed electrical stimulation in conscious postinfarction dogs. Naunyn Schmiedebergs Arch Pharmacol 346:213–218

    CAS  Article  PubMed  Google Scholar 

  21. Dib N, Diethrich EB, Campbell A et al. (2006) A percutaneous swine model of myocardial infarction. J Pharmacol Toxicol Methods 53:256–263

    CAS  Article  PubMed  Google Scholar 

  22. Katori R, Yamashita K, Miyazaki T et al. (1995) Beta-adrenergic stimulation induces ST-segment elevation in dogs with healing myocardial infarction. Tohoku J Exp Med 177:233–248

    CAS  Article  PubMed  Google Scholar 

  23. Chua T, Kiat H, Germano G et al. (1993) Rapid back to back adenosine stress/rest technetium-99 m teboroxime myocardial perfusion SPECT using a triple-detector camera. J Nucl Med 34:1485–1493

    CAS  PubMed  Google Scholar 

  24. Berman DS, Germano G, Shaw LJ (1999) The role of nuclear cardiology in clinical decision making. Semin Nucl Med 29:280–297

    CAS  Article  PubMed  Google Scholar 

  25. Acampa W, Di Benedetto C, Cuocolo A (2000) An overview of radiotracers in nuclear cardiology. J Nucl Cardiol 7:701–707

    CAS  Article  PubMed  Google Scholar 

  26. Lee CH, Bradley G, Zhang JT et al. (1993) Differential expression of P-glycoprotein genes in primary rat hepatocyte culture. J Cell Physiol 157:392–402

    CAS  Article  PubMed  Google Scholar 

  27. Mayer R, Kartenbeck J, Buchler M et al. (1995) Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J Cell Biol 131:137–150

    CAS  Article  PubMed  Google Scholar 

  28. Agrawal M, Abraham J, Balis FM et al. (2003) Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 9:650–656

    CAS  PubMed  Google Scholar 

  29. Gatmaitan ZC, Arias IM (1993) Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 24:77–97

    CAS  Article  PubMed  Google Scholar 

  30. Qadir M, O'Loughlin KL, Fricke SM et al. (2005) Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11:2320–2326

    CAS  Article  PubMed  Google Scholar 

  31. van Dongen AJ, van Rijk PP (2001) Minimizing liver, bowel, and gastric activity in myocardial perfusion SPECT. J Nucl Med 41: 1315–1317

    Google Scholar 

Download references

Acknowledgments

This work was supported, in part, by the following research grants: 2009DFB30040 from the international cooperation projects of the Chinese Ministry of Science and Technology, 20070420165 from the National Science Foundation for Postdoctoral Scientists of China, 2007AA3CS085 from the Science and Technology Tackle Key Problem Plan Foundation of Harbin. The authors wish to thank Drs. Fan Wang and Bing Jia from Peking University for technical support.

Author information

Affiliations

  1. Department of Pharmacology, Harbin Medical University, 157 Baojian Street, Nangang District, Harbin, Heilongjiang, 150001, People’s Republic of China

    Lihong Bu, Baofeng Yang & Baozhong Shen

  2. Department of Medical Imaging, the Fourth Hospital of Harbin Medical University, 31 Yinhang Street, Nangang District, Harbin, Heilongjiang, 150001, People’s Republic of China

    Lihong Bu, Renfei Li, Zhongnan Jin, Xiaofei Wen & Baozhong Shen

  3. Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, 94305-5484, USA

    Lihong Bu & Xiaoyuan Chen

  4. School of Health Sciences, Purdue University, West Lafayette, IN, 47907-2036, USA

    Shuang Liu

  5. Laboratory for Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), 31 Center Drive, Suite 1C14, Bethesda, MD, 20892-2281, USA

    Xiaoyuan Chen

Authors
  1. Lihong Bu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renfei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhongnan Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaofei Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shuang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Baofeng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Baozhong Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiaoyuan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Baozhong Shen or Xiaoyuan Chen.

Additional information

Lihong Bu and Renfei Li contributed equally to this work

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bu, L., Li, R., Jin, Z. et al. Evaluation of 99  mTcN-MPO as a New Myocardial Perfusion Imaging Agent in Normal Dogs and in an Acute Myocardial Infarction Canine Model: Comparison with 99  mTc-Sestamibi. Mol Imaging Biol 13, 121–127 (2011). https://doi.org/10.1007/s11307-010-0304-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-010-0304-2

Key words

  • 99  mTcN-MPO
  • Myocardial perfusion imaging
  • Biodistribution
  • Liver clearance
  • Myocardial infarction
  • SPECT